by Steven Grossman | Sep 17, 2025 | Short Takes and Updates
To many of us, advisory committee meetings are emblematic of an FDA that listens, is open to diverse viewpoints, and is willing to change direction when other views prove compelling. FDA never yields the authority to decide. Yet, agency decisions about high-profile...
by Steven Grossman | Sep 15, 2025 | Uncategorized
This week’s questions:Is Secretary Kennedy at risk of losing his job?What is Kenvue? Doesn’t J&J make Tylenol?How realistic is it to dramatically shorten product review cycles? ———Q: Is Secretary Kennedy at risk of losing his job? A: Many...
by Steven Grossman | Sep 7, 2025 | Uncategorized
This week’s questions:What’s at stake when a CDC director won’t sign off on the Administration’s vaccine policies, is fired, and several senior center leaders resign? What happens next at CDC?What are the possible impacts of the CDC situation on FDA and...
by Steven Grossman | Sep 5, 2025 | Short Takes and Updates
FDA Matters doesn’t cover the news….we provide analysis of what’s behind the newsThis week: My Comment on Secretary Kennedy’s September 4 Appearance Before the Senate Finance CommitteeMAHA Strategy Plan Likely to Be Released Week of September 8.MAHA...
by Steven Grossman | Sep 2, 2025 | Uncategorized
———This week’s questions:Did your column on MAHA intend to deliver a specific message to journalists and lead advocacy groups? What is the most critical FDA issue in September? What are some FDA issues that are simmering and will eventually surface?...
